Palliative dilation of esophageal carcinoma

Gastrointest Endosc. 1985 Apr;31(2):61-3. doi: 10.1016/s0016-5107(85)71993-1.


The authors' experience with palliative dilation of 46 consecutive patients evaluated for squamous cell carcinoma of the esophagus was retrospectively reviewed. Thirty-nine of 46 patients (85%) underwent dilation in order to palliate symptoms, enable endoscopy and biopsy, or prepare for placement of an esophageal prosthesis. Thirty-two of the 46 patients (70%) were treated with radiation therapy and seven (15%) underwent placement of an esophageal prosthesis. Thirty-five of the 39 patients dilated (90%) noted improvement in swallowing, allowing resumption of a soft or regular diet. Complications were noted in three of the 39 patients dilated (8%). The authors conclude that peroral dilation is a safe, effective, and probably underutilized method of palliation in patients with squamous cell esophageal carcinoma.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Squamous Cell / complications
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / therapy*
  • Deglutition Disorders / etiology
  • Deglutition Disorders / therapy
  • Dilatation / adverse effects
  • Esophageal Neoplasms / complications
  • Esophageal Neoplasms / mortality
  • Esophageal Neoplasms / therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Palliative Care*
  • Prognosis
  • Retrospective Studies